Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients

Por Bank, J. R., Rabelink, T. J., de Fijter, J. W., Reinders, M. E. J.
Publicado no J Immunol Res (2015)

A pharmacological rationale for improved everolimus dosing in oncology and transplant patients

Por ter Heine, R., van Erp, N. P., Guchelaar, H. J., de Fijter, J. W., Reinders, M. E. J., van Herpen, C. M., Burger, D. M., Moes, D. J. A. R.
Publicado no Br J Clin Pharmacol (2018)

Presence of intragraft B cells during acute renal allograft rejection is accompanied by changes in peripheral blood B cell subsets

Por Heidt, S., Vergunst, M., Anholts, J. D. H., Swings, G. M. J. S., Gielis, E. M. J., Groeneweg, K. E., Witkamp, M. J., de Fijter, J. W., Reinders, M. E. J., Roelen, D. L., Eikmans, M., Claas, F. H. J.
Publicado no Clin Exp Immunol (2019)